Bexarotene-Induced Dyslipidemia and Central Hypothyroidism in a Patient With Sezary Syndrome

Abstract

We report a patient with Sezary syndrome (cutaneous T-cell lymphoma) who developed severe central hypothyroidism and mixed hyperlipidemia due to the bexarotene treatment (a synthetic retinoid analog with specific affinity for retinoid X receptor used in the treatment of Sezary syndrome). The other pituitary functions were found to be normal. These are rare adverse effects of bexarotene treatment and there are a few case reports in literature. Management of the adverse events could be done by nicotinic acid or fenofibrates, statins and L-thyroxin replacement. In this case we managed the patient by nicotinic acid, statin and L-thyroxin for 2 years.




J Endocrinol Metab. 2014;4(4):115-117
doi: http://dx.doi.org/10.14740/jem222w